# PM Peer Review: F2 Formulary Data Source Integration

## Skill Vesion

v1.2

## Review Verdict

APPROVE WITH CHANGES

## Top Findings

- S1: The PRD does not document regulatory, compliance, and source dependency assumptions for formulary data delivery.
- S1: Success metrics are partly measurable, but the routing metric and user experience standard are not bounded by explicit latency, accuracy slices, or reporting windows.
- S1: The business rules engine is central to the solution but lacks scope boundaries for what plan logic it will and will not encode in this phase.
- S2: Secondary users include members, but the rollout and validation model is still written entirely as an internal systems handoff.

## Findings Table

| Severity | Section | Issue | Why it matters | Recommended fix |
| --- | --- | --- | --- | --- |
| S1 | Problem Statement / Scope | The PRD references regulatory risk, but does not specify compliance constraints, data usage boundaries, or required legal/privacy review. | Medication coverage information is sensitive and high-risk; approval should not proceed without explicit compliance handling. | Add risks/dependencies covering compliance review, permitted data usage, audit needs, and external vendor obligations. |
| S1 | Success Metrics | "Enable medication coverage queries with intelligent routing" is not a quantifiable KPI and no metric includes measurement cadence or baseline. | Reviewers cannot assess readiness without knowing how routing quality and user experience will be measured over time. | Replace with measurable KPIs such as routing precision/recall, p95 latency, and plan coverage validation rate, each with baseline and time window. |
| S1 | Proposed Solution / Scope | The business rules engine is mentioned but the PRD does not define which formulary logic is in scope for phase one. | This creates implementation ambiguity and risk of uncontrolled expansion during delivery. | Explicitly list supported rule categories for Q2 and move advanced rule classes to out-of-scope. |
| S2 | Target Users / Definition of Done | Member impact is stated, but there is no acceptance criterion tied to member-safe fallback or agent-facing confidence messaging. | The feature could technically launch while still exposing poor failure handling in live support flows. | Add acceptance criteria for fallback copy, confidence signaling, and agent workflow behavior during RxFlex unavailability. |

## Missing Decisions

- What compliance or legal review is required before exposing formulary responses in production?
- Which business rule categories must be supported in phase one versus deferred?
- What latency standard defines an acceptable formulary query experience for the BSC launch?

## Revision Plan

1. Add a risks/dependencies section for RxFlex contract, compliance review, outage handling, and data stewardship.
2. Rewrite success metrics so all KPIs are explicitly measurable, time-bound, and instrumentable.
3. Narrow the business rules engine scope by naming the exact rule types included in this release.
4. Strengthen definition of done with member-safe fallback behavior and operational sign-off criteria.

## Quality Score

67/100. The document has strong problem framing, but approval readiness is limited by under-specified compliance, measurement, and rule-scope decisions.
